New Rochelle, NY, September 7, 2016--A new study shows significant improvement in critical components of reading, including decoding and vocabulary, among children treated with atomoxetine compared to placebo. Atomoxetine treatment was also associated with significant reductions in symptoms of attention-deficit/hyperactivity disorder (ADHD) in children with both dyslexia and ADHD or ADHD alone, as reported in the study published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free to download on the Journal of Child and Adolescent Psychopharmacology website until October 7, 2016.
Researchers Sally Shaywitz, MD and Bennett Shaywitz, MD, Yale University (New Haven, CT), Linda Wietecha, Lilly USA (Indianapolis, IN), Sharon Wigal, PhD, AVIDA (Newport Beach, CA), Keith McBurnett, PhD, University of California, San Francisco, David Williams, inVentiv Health Clinical, and William Kronenberger, PhD, Indiana University School of Medicine (Indianapolis, IN), and Stephen Hooper, PhD, University of North Carolina, School of Medicine (Chapel Hill) evaluated reading ability and ADHD symptoms in children aged 10-16 years who had dyslexia, dyslexia and ADHD, or only ADHD and received either atomoxetine or placebo for 16 weeks. The authors report their results in the article "Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial."
"Treatments for dyslexia are essential for the millions of children who suffer from this disorder. This unique study offers a potential promising psychopharmacological intervention for the treatment of dyslexia," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
About the Journal
Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published ten times per year online with Open Access options and in print. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.